Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 17/20 | 0.70 |
| ▸ | MAP4K2 | Q12851 | 17/20 | 0.70 |
| ▸ | ABL1 | P00519 | 2/20 | 0.68 |
| ▸ | BMX | P51813 | 2/20 | 0.68 |
| ▸ | BCR | P11274 | 1/20 | 0.68 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.68 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.68 |
| ▸ | LCK | P06239 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19865444 | 0.92 | TNK2 (0.73) | TNK2MAP4K2ABL1BMXBCR | |
| SCHEMBL19922718 | 0.90 | TNK2 (0.76) | TNK2MAP4K2ABL1BMXBCR | |
| SCHEMBL19922758 | 0.90 | TNK2 (0.78) | TNK2MAP4K2ABL1BMXBCR | |
| SCHEMBL19922745 | 0.88 | TNK2 (0.84) | TNK2MAP4K2ABL1BMXBCR | |
| SCHEMBL19922940 | 0.86 | TNK2 (0.84) | TNK2MAP4K2ABL1BMXBCR | |
| SCHEMBL19922715 | 0.85 | TNK2 (0.70) | TNK2MAP4K2ABL1BMXBCR | |
| SCHEMBL19922946 | 0.84 | TNK2 (0.73) | TNK2MAP4K2ABL1BMXBCR | |
| SCHEMBL19922743 | 0.84 | TNK2 (0.73) | TNK2MAP4K2ABL1BMXBCR | |
| SCHEMBL19922634 | 0.84 | TNK2 (0.77) | TNK2MAP4K2ABL1BMXBCR | |
| SCHEMBL19929613 | 0.83 | TNK2 (0.65) | TNK2MAP4K2ABL1BMXBCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10059717-B2 | Urea compounds containing 3,4-dihydropyrimido[4,5-D]pyrimidin-2(1H)-one skeleton as protein kinase inhibitors | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2018-08-28 | — | — | US | claimed |
| US-20180065970-A1 | UREA COMPOUNDS CONTAINING 3,4-DIHYDROPYRIMIDO[4,5-D]PYRIMIDIN-2(1H)-ONE SKELETON AS PROTEIN KINASE INHIBITORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2018-03-08 | — | — | US | claimed |
| US-10059717-B2 | Urea compounds containing 3,4-dihydropyrimido[4,5-D]pyrimidin-2(1H)-one skeleton as protein kinase inhibitors | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2018-08-28 | — | — | US | disclosed |
| US-20180065970-A1 | UREA COMPOUNDS CONTAINING 3,4-DIHYDROPYRIMIDO[4,5-D]PYRIMIDIN-2(1H)-ONE SKELETON AS PROTEIN KINASE INHIBITORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2018-03-08 | — | — | US | disclosed |
| US-20180065970-A1 | UREA COMPOUNDS CONTAINING 3,4-DIHYDROPYRIMIDO[4,5-D]PYRIMIDIN-2(1H)-ONE SKELETON AS PROTEIN KINASE INHIBITORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2018-03-08 | — | — | US | disclosed |
| US-20180065970-A1 | UREA COMPOUNDS CONTAINING 3,4-DIHYDROPYRIMIDO[4,5-D]PYRIMIDIN-2(1H)-ONE SKELETON AS PROTEIN KINASE INHIBITORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10059717-B2 | Urea compounds containing 3,4-dihydropyrimido[4,5-D]pyrimidin-2(1H)-one skeleton as protein kinase inhibitors | MAP4K2, CMPK1, MTOR | TNK2 230/4885MAP4K2 1/4885ABL1 118/4885 |
| US-20180065970-A1 | UREA COMPOUNDS CONTAINING 3,4-DIHYDROPYRIMIDO[4,5-D]PYRIMIDIN-2(1H)-ONE SKELETON AS PROTEIN KINASE INHIBITORS | MAP4K2, CMPK1, MTOR | TNK2 230/4885MAP4K2 1/4885ABL1 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.